Approved Ligands

Ponatinib (AP24534) is a novel, potent multi-target inhibitor of Abl, PDGFRα, VEGFR2, FGFR1 and Src with IC50 of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM and 5.4 nM, respectively.A Bcr-Abl (Bcr and c-Abl fusion), FGFR, and Flk-1 inhibitor.

Ponatinib (AP24534) is a novel, potent multi-target inhibitor of Abl, PDGFRα, VEGFR2, FGFR1 and Src with IC50 of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM and 5.4 nM, respectively.A Bcr-Abl (Bcr and c-Abl fusion), FGFR, and Flk-1 inhibitor.

Potent sphingosine-1-phophate receptor agonist.

Potent sphingosine-1-phophate receptor agonist.

Potent sphingosine-1-phophate receptor agonist.

Potent sphingosine-1-phophate receptor agonist.

Potent sphingosine-1-phophate receptor agonist.

Potent sphingosine-1-phophate receptor agonist.

InformationPractolol is a selective antagonist of β-1 adrenergic receptor that has been used in the emergency treatment of cardiac arrhythmias. Practolol has anti-hyperstensive activity.

InformationPractolol is a selective antagonist of β-1 adrenergic receptor that has been used in the emergency treatment of cardiac arrhythmias. Practolol has anti-hyperstensive activity.

InformationPractolol is a selective antagonist of β-1 adrenergic receptor that has been used in the emergency treatment of cardiac arrhythmias. Practolol has anti-hyperstensive activity.

InformationPractolol is a selective antagonist of β-1 adrenergic receptor that has been used in the emergency treatment of cardiac arrhythmias. Practolol has anti-hyperstensive activity.